{"id":3079,"date":"2025-03-05T16:45:40","date_gmt":"2025-03-05T13:45:40","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3079"},"modified":"2025-03-07T12:54:07","modified_gmt":"2025-03-07T09:54:07","slug":"pepgen-temporarily-pauses-exon-51-skipping-study","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/pt\/pepgen-temporarily-pauses-exon-51-skipping-study\/","title":{"rendered":"PepGen interrompe temporariamente o estudo de salto do exon 51"},"content":{"rendered":"<p class=\"wp-block-paragraph\">A PepGen, uma empresa de biotecnologia em est\u00e1gio cl\u00ednico que promove a pr\u00f3xima gera\u00e7\u00e3o de terapias de oligonucleot\u00eddeos com o objetivo de transformar o tratamento de doen\u00e7as neuromusculares e neurol\u00f3gicas graves, anunciou hoje sua decis\u00e3o volunt\u00e1ria de pausar temporariamente o estudo de Fase 2 CONNECT2-EDO51 do PGN-EDO51 em pacientes com distrofia muscular de Duchenne (DMD) at\u00e9 que a empresa possa revisar os resultados da coorte de 10 mg\/kg no estudo de Fase 2 CONNECT1-EDO51 em andamento.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As duas primeiras coortes do estudo CONNECT1 est\u00e3o totalmente inscritas e os dados da coorte de 10 mg\/kg s\u00e3o esperados para o terceiro trimestre de 2025. Nenhum novo problema de seguran\u00e7a relacionado ao PGN-EDO51 foi observado desde a \u00faltima atualiza\u00e7\u00e3o de seguran\u00e7a da empresa em 23 de janeiro de 2025.<\/p>","protected":false},"excerpt":{"rendered":"<p>PepGen, a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) until the Company can review results from the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3081,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[137,275,122,193,194,77,273,274],"class_list":["post-3079","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-clinical-trial","tag-connect1-edo51","tag-exon-51","tag-exon-51-skipping","tag-exon-51-treatment","tag-exon-skipping","tag-pepgen","tag-pgn-edo51"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/3079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/comments?post=3079"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/posts\/3079\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media\/3081"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/media?parent=3079"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/categories?post=3079"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/pt\/wp-json\/wp\/v2\/tags?post=3079"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}